| 9.555 0.315 (3.41%) | 05-14 15:13 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.65 | 1-year : | 13.6 |
| Resists | First : | 9.97 | Second : | 11.65 |
| Pivot price | 9.46  |
|||
| Supports | First : | 9.06 |
Second : | 8.5 |
| MAs | MA(5) : | 9.36 |
MA(20) : | 9.49 |
| MA(100) : | 9.66 |
MA(250) : | 10.63 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 34.4 |
D(3) : | 32.2 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 16.44 | Low : | 6.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OCUL ] has closed below upper band by 45.5%. Bollinger Bands are 72.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.36 - 9.42 | 9.42 - 9.47 |
| Low: | 8.79 - 8.87 | 8.87 - 8.94 |
| Close: | 9.12 - 9.24 | 9.24 - 9.35 |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Fri, 08 May 2026
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fri, 08 May 2026
Twelve new Ocular employees get stock awards tied to 169,200 shares - Stock Titan
Fri, 01 May 2026
How Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 Trial - Yahoo Finance
Fri, 01 May 2026
OCULAR THERAPEUTIX, INC ($OCUL) CEO 2025 Pay Revealed - Quiver Quantitative
Wed, 29 Apr 2026
Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data - Yahoo Finance
Mon, 27 Apr 2026
Ocular lines up May talks on AMD trial data and investor webcasts - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 218 (M) |
| Shares Float | 215 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 90.3 (%) |
| Shares Short | 24,530 (K) |
| Shares Short P.Month | 23,680 (K) |
| EPS | -1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.02 |
| Profit Margin | 0 % |
| Operating Margin | -526.5 % |
| Return on Assets (ttm) | -26.7 % |
| Return on Equity (ttm) | -54.9 % |
| Qtrly Rev. Growth | -22.4 % |
| Gross Profit (p.s.) | -0.7 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -1.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -205 (M) |
| Levered Free Cash Flow | -128 (M) |
| PE Ratio | -6.7 |
| PEG Ratio | 0 |
| Price to Book value | 3.13 |
| Price to Sales | 39.82 |
| Price to Cash Flow | -10.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|